Filing Analysis
PDS Biotechnology Corp has announced a significant reduction in force affecting approximately 36% of its workforce to align expenses with the development of PDS0301. Additionally, the company terminated its Chief Operating Officer, Stephan Toutain, without cause.
🚩 Red Flags
- Significant workforce reduction (36%) suggests aggressive cost-cutting/liquidity management.
- Departure of a key C-suite officer (COO) during a period of restructuring.
- One-time cash expenditure of $842,000 for severance in a micro-cap biotech context.
📋 Key Facts
- Reduction in force (RIF) approved by the Board on August 6, 2026.
- RIF affects approximately 36% of the total workforce.
- One-time charge of approximately $842,000 expected in Q3 2026 for severance and benefits.
- Chief Operating Officer Stephan Toutain was terminated without cause on August 21, 2026.
- COO is entitled to 12 months of base salary and 12 months of COBRA health care contributions.
PDS Biotechnology Corp held its 2026 annual meeting of stockholders on August 10, 2026. The primary outcome was the successful approval of an amendment to increase authorized common stock from 150 million to 300 million shares.
🚩 Red Flags
- Significant increase in authorized share count (doubled from 150M to 300M), which typically facilitates future equity dilution through secondary offerings or warrants.
📋 Key Facts
- Annual Meeting held on August 10, 2026.
- Stockholders approved an amendment to increase authorized common stock from 150,000,000 to 300,000,000 shares.
- Kamil Ali-Jackson and Ilian Iliev were elected as Class B directors.
- KPMG US LLP was ratified as the independent registered public accounting firm for fiscal year ending Dec 31, 2026.
- Quorum was established with 56.60% of shares (31,594,722) represented at the meeting.
PDS Biotechnology Corporation issued an 8-K to furnish its quarterly business update and financial results for the period ended June 30, 2026. The filing serves as a formal announcement of the company's operational and financial standing for the second quarter.
📋 Key Facts
- Report date: August 13, 2026
- Reporting period: Quarter ended June 30, 2026
- The filing includes a press release (Exhibit 99.1) detailing business updates and financial results.
- Information is 'furnished' rather than 'filed', limiting liability under Section 18 of the Exchange Act.
PDS Biotechnology Corporation issued a shareholder letter via Regulation FD disclosure on August 11, 2026. The filing serves to furnish information posted on the company's investor relations website.
📋 Key Facts
- The company issued a letter to shareholders dated August 11, 2026.
- Information was disclosed pursuant to Regulation FD (Item 7.01).
- The disclosure is furnished but not 'filed' for purposes of Section 18 liability.
PDS Biotechnology Corporation received a deficiency letter from Nasdaq because its common stock has traded below the $1.00 minimum bid price requirement for 30 consecutive business days. The company has been granted a 180-day compliance period ending January 26, 2027.
🚩 Red Flags
- Delisting notice/Non-compliance with minimum bid price requirement
- Potential for a reverse stock split to regain compliance (often dilutive or signaling distress)
- Risk of permanent delisting if compliance is not met by January 26, 2027
📋 Key Facts
- Received deficiency letter from Nasdaq Listing Qualifications Department on July 30, 2026.
- Violation of Nasdaq Listing Rule 5550(a)(2) regarding the $1.00 minimum bid price requirement.
- Compliance period granted for 180 calendar days, expiring January 26, 2027.
- To regain compliance, the stock must close at or above $1.00 for at least 10 consecutive business days during the period.
- The company explicitly mentioned considering a reverse stock split as a potential remedy.
PDS Biotechnology closed a financing arrangement with YA II PN, LTD involving a $6M promissory note and warrants, while simultaneously establishing a $50M 'at-the-market' (ATM) equity offering program. The company used the initial funds to fully redeem existing Senior Secured Convertible Debentures at 103% of principal.
🚩 Red Flags
- Significant potential dilution: The $50M ATM offering is very large relative to typical micro-cap equity bases.
- High-cost debt: The 10% interest rate on the new promissory note is substantial.
- Dependence on a single investor: YA II PN, LTD is both the lender and an affiliate of one of the ATM agents (Yorkville Securities).
- Debt cycling: The company is essentially borrowing new funds to pay off old debt (the Debentures).
📋 Key Facts
- Issued a Promissory Note with a face value of $6,000,000 for a purchase price of $5,760,000.
- Promissory Note carries a 10% annual interest rate with a 12-month maturity.
- Issued a warrant to purchase up to 2,158,274 shares at an exercise price of $1.1824 per share.
- Entered into a Sales Agreement for an ATM offering of up to $50,000,000 in common stock via Yorkville Securities and B. Riley Securities.
- Fully redeemed and terminated existing Senior Secured Convertible Debentures at 103% of principal plus accrued interest.
- ATM proceeds are earmarked first for Promissory Note amortization, then for working capital.
PDS Biotechnology Corp has announced that its 2026 Annual Meeting of Stockholders is scheduled for August 10, 2026. The company also established a deadline of June 25, 2026, for the submission of stockholder proposals under Rule 14a-8.
📋 Key Facts
- 2026 Annual Meeting of Stockholders date: August 10, 2026
- Deadline for stockholder proposals (Rule 14a-8): June 25, 2026
- Definitive Proxy Statement on Schedule 14A to be filed separately
PDS Biotechnology Corp announced that it has regained compliance with the Nasdaq Minimum Bid Price Requirement. Nasdaq has officially closed the matter following a deficiency notice originally issued on February 25, 2026.
🚩 Red Flags
- The company previously struggled to maintain a share price above $1.00 for 30 consecutive business days, indicating historical volatility or downward pressure on the stock.
📋 Key Facts
- The company received a deficiency letter on February 25, 2026, regarding the $1.00 minimum bid price requirement (Nasdaq Listing Rule 5550(a)(2)).
- On June 2, 2026, the company received written notice from Nasdaq confirming it has regained compliance.
- Nasdaq has officially closed the matter.
PDS Biotechnology Corporation reported its financial results for the first quarter ended March 31, 2026, and provided a general business update. The information was disclosed via a press release furnished under Item 2.02.
📋 Key Facts
- Financial results released for the quarter ended March 31, 2026
- Press release issued on May 13, 2026
- The filing includes a business update in addition to financial figures
- Information is furnished under Item 2.02 and is not deemed 'filed' for liability purposes
PDS Biotechnology entered into a $6 million financing agreement with Yorkville (YA II PN, LTD) consisting of a promissory note, warrants, and an at-the-market (ATM) offering. The arrangement includes a mandatory sweep of ATM proceeds to service the debt, significantly restricting the company's use of future equity capital.
🚩 Red Flags
- Financing provided by Yorkville (YA II PN, LTD), often associated with dilutive 'death spiral' structures.
- Mandatory 100% sweep of ATM proceeds to pay down debt limits operational flexibility.
- Default-triggered conversion rights at a discount (92-95% of VWAP).
- The requirement to repay existing debt as a closing condition suggests refinancing pressure or liquidity constraints.
📋 Key Facts
- Issued a $6,000,000 Promissory Note at a 4% original issue discount ($5,760,000 purchase price).
- The note carries a 10% annual interest rate and matures in 12 months.
- Issued a 5-year warrant to purchase 2,158,274 shares at an exercise price of $1.1824.
- Established an ATM facility where 100% of net proceeds must be applied to the next amortization payment of the note.
- If ATM proceeds exceed the current amortization payment, 60% of the excess must be applied to future debt payments.
- Closing is contingent upon the repayment or termination of the company's existing indebtedness.
PDS Biotechnology Corporation updated its corporate presentation deck on April 24, 2026. The updated deck was filed as an exhibit to provide current information to investors and the public.
📋 Key Facts
- The filing occurred on April 24, 2026.
- The company updated its corporate presentation deck (Exhibit 99.1).
- The report was filed under Item 8.01 (Other Events) and Item 9.01 (Financial Statements and Exhibits).
PDS Biotechnology announced the publication of Phase 2 clinical and immunological biomarker data for its PDS01ADC candidate in the peer-reviewed journal JCO Oncology Advances. The data pertains to Stage 1 of a trial evaluating the tumor-targeted IL-12 immunocytokine.
📋 Key Facts
- Clinical and immunological biomarker data from Stage 1 of a Phase 2 trial was published.
- The drug candidate evaluated is PDS01ADC, a tumor-targeted IL-12 immunocytokine.
- The data was published in the March 10, 2026 issue of Journal of Clinical Oncology (JCO) Oncology Advances.
- The 8-K was filed on April 15, 2026, following the press release issued the same day.
PDS Biotechnology Corporation furnished its financial results for the fiscal year ended December 31, 2025, along with a business update. The disclosure was made via a press release attached as Exhibit 99.1 under Item 2.02.
📋 Key Facts
- Reported financial results for the full year ended December 31, 2025
- Included a general business update in the announcement
- Filing date and earliest event date is March 30, 2026
- Information is furnished under Item 2.02 and is not deemed 'filed' for Section 18 liability purposes
PDS Biotechnology Corporation received a deficiency notice from Nasdaq on February 25, 2026, for failing to maintain the minimum $1.00 bid price requirement for 30 consecutive business days. The company has until August 24, 2026, to regain compliance or face potential delisting.
🚩 Red Flags
- Failure to maintain a $1.00 minimum bid price indicates significant loss of market value.
- Potential for a reverse stock split, which is often viewed negatively by the market.
- Risk of delisting from the Nasdaq Capital Market if compliance is not met.
📋 Key Facts
- Received Nasdaq deficiency letter on February 25, 2026, regarding Listing Rule 5550(a)(2).
- Common stock bid price was below $1.00 for 30 consecutive business days.
- The company has an initial 180-day compliance period ending August 24, 2026.
- To regain compliance, the stock must close at or above $1.00 for at least 10 consecutive business days.
- The company may be eligible for a second 180-day extension if it meets other listing standards.
- Management explicitly mentioned a reverse stock split as a potential option to regain compliance.
PDS Biotechnology Corporation filed an updated corporate presentation deck on February 23, 2026, for use in upcoming investor communications.
📋 Key Facts
- The filing was made under Item 8.01 (Other Events) on February 23, 2026.
- The updated corporate presentation is included as Exhibit 99.1.
- The document was signed by Frank Bedu-Addo, Ph.D., President and Chief Executive Officer.
PDS Biotechnology Corporation announced a protocol amendment to its Phase 3 VERSATILE-003 clinical trial, adding progression-free survival (PFS) as an interim primary endpoint to support a potential accelerated approval pathway for PDS0101 in HPV16-positive recurrent/metastatic head and neck cancer. The FDA's 30-day review period passed without objection, and the company is proceeding with the amended protocol.
🚩 Red Flags
- Clinical-stage biotech with no approved products — high cash burn risk (not directly stated in filing but inherent to profile)
- Accelerated approval pathway via PFS is not guaranteed and depends on trial data meeting FDA thresholds
- No financial data disclosed — investors cannot assess remaining cash runway from this filing alone
📋 Key Facts
- Protocol amendment to Phase 3 VERSATILE-003 trial adds progression-free survival (PFS) as interim primary endpoint for potential accelerated approval
- Median overall survival (mOS) remains the primary endpoint for full approval
- Target indication: PDS0101 in HPV16-positive recurrent and/or metastatic head and neck cancer
- FDA's standard 30-day IND amendment review period passed without objection as of February 20, 2026
- Amendment follows prior Type C meeting with FDA and subsequent post-meeting communication
- Filed under Item 8.01 (Other Events) — disclosure via press release (Exhibit 99.1)
- Signed by Frank Bedu-Addo, Ph.D., President and CEO
- Listed on Nasdaq Capital Market; common stock par value $0.00033/share
PDS Biotechnology Corporation announced the presentation of clinical study results for its investigational drug PDS01ADC at an AACR special conference. The data pertains to a National Cancer Institute-led study regarding prostate cancer research.
📋 Key Facts
- Company presented results for PDS01ADC, an investigational Interleukin-12 (IL-12) tumor targeted immunocytokine.
- The presentation occurred at the American Association of Cancer Research (AACR) special conference on prostate cancer research in Boston, MA.
- The study was led by the National Cancer Institute (NCI).
- Conference dates: January 20-22, 2026.
PDS Biotechnology Corporation announced that the U.S. Patent Office has issued a Notice of Allowance for its lead asset, PDS0101. This represents a positive regulatory/intellectual property milestone for the company's primary drug candidate.
📋 Key Facts
- U.S. Patent Office issued a Notice of Allowance for the Company’s lead asset, PDS0101.
- The announcement was made via press release on January 22, 2026.
- Lead asset is identified as PDS0101.
PDS Biotechnology Corp has submitted a protocol amendment to the FDA for its Phase 3 VERSATILE-003 clinical trial. The amendment seeks to introduce an earlier primary endpoint (progression-free survival) to potentially support accelerated approval of PDS0101.
📋 Key Facts
- Company submitted a protocol amendment to the FDA on January 9, 2026.
- The amendment concerns the Phase 3 VERSATILE-003 clinical trial for PDS0101.
- Proposed change: Adding progression-free survival as a primary endpoint that can be evaluated earlier with statistical power.
- Median overall survival remains the primary endpoint required for full approval per FDA recommendation.
PDS Biotechnology Corporation announced that the Japan Patent Office has issued Patent No. 7783866 for its PDS0101 product, covering broad composition of matter and methods of use. This patent expands the company's intellectual property protections in Japan, complementing existing patents in the US, China, Australia, and Hong Kong.
📋 Key Facts
- Japan Patent Office issued Patent No. 7783866 for PDS0101 on December 9, 2025.
- The patent includes broad composition of matter and methods of use claims.
- Existing IP estate covers the US, China, Australia, and Hong Kong.
- Combined with biologics exclusivity in the US, protection for PDS0101 is anticipated into the 2040s.
PDS Biotechnology Corporation announced that the FDA has accepted its request for a Type C Meeting, which is scheduled to take place later this month.
📋 Key Facts
- FDA has accepted the company's request for a Type C Meeting.
- The meeting is scheduled to occur in December 2025.
- A press release was issued on December 2, 2025, regarding this development.
PDS Biotechnology Corporation issued an 8-K to furnish a press release regarding its clinical program updates and financial results for the quarter ended September 30, 2025.
📋 Key Facts
- The filing is pursuant to Item 2.02 (Results of Operation and Financial Condition).
- The report covers the quarterly period ending September 30, 2025.
- The company provided an update on its clinical programs via a press release dated November 13, 2025.
PDS Biotechnology Corp announced a significant equity offering involving the issuance of common stock, pre-funded warrants, and common warrants to raise approximately $10.4 million in net proceeds. The filing also includes a warrant amendment that significantly lowers the exercise price for existing warrants from $1.50 to $1.00.
🚩 Red Flags
- Significant dilution: The issuance of millions of warrants (common and pre-funded) represents substantial potential future dilution for existing shareholders.
- Warrant Repricing: The reduction of the exercise price from $1.50 to $1.00 on existing warrants is a dilutive event that favors warrant holders at the expense of current equity holders.
- Capital Raise Necessity: While cash position is reported at $26.2M, the immediate need for an $11M gross raise suggests high burn rates typical of biotech firms in clinical stages.
📋 Key Facts
- Offering of 5,741,000 shares of common stock at $0.91 per share.
- Issuance of pre-funded warrants (59,000) and common warrants (up to 5,800,000).
- Expected net proceeds of approximately $10.4 million for R&D and general corporate purposes.
- Warrant amendment reduces exercise price of existing warrants from $1.50 to $1.00 per share.
- Placement agent (Craig-Hallum Capital Group LLC) to receive a 6.0% cash fee plus up to $100,000 in expenses.
- Company reported approximately $26.2 million in cash and cash equivalents as of September 30, 2025.
PDS Biotechnology Corporation issued a press release regarding positive clinical and translational data presented at the 2025 Society for Immunotherapy of Cancer Annual Meeting. The data focuses on immune-driven mechanisms for their investigational therapies PDS0101 and PDS01ADC.
📋 Key Facts
- Announced presentation of clinical/translational data at the 2025 Society for Immunotherapy of Cancer (SITC) Annual Meeting.
- Data highlights immune-driven mechanisms and biomarkers related to HPV16-targeted immunotherapy PDS0101.
- Data also covers investigational immunocytokine PDS01ADC.
PDS Biotechnology Corporation announced it has requested a meeting with the FDA to discuss an expedited approval pathway for its candidate PDS0101 in treating HPV16+ Head and Neck Cancer.
📋 Key Facts
- Company requested an FDA meeting on October 29, 2025.
- Objective of meeting is to explore an expedited approval pathway.
- Target indication: PDS0101 for HPV16+ Head and Neck Cancer.
PDS Biotechnology Corporation issued an 8-K to announce the release of sub-analysis data from its Phase 2 VERSATILE-002 clinical trial. The data specifically focuses on a cohort of patients with low PD-L1 expression (CPS 1-19).
📋 Key Facts
- Announcement date: September 18, 2025.
- Clinical Trial: VERSATILE-002 Phase 2 trial.
- Data Focus: Sub-analysis of patients with low PD-L1 expression (CPS 1-19).
- Context: Data is derived from the final data of the recently completed trial.
PDS Biotechnology Corporation filed an 8-K to announce the update of its corporate presentation deck as of August 25, 2025.
📋 Key Facts
- The company updated its corporate presentation deck on August 25, 2025.
- The updated presentation is filed as Exhibit 99.1.
PDS Biotechnology Corporation announced topline survival data from its Phase 2 VERSATILE-002 clinical trial. The study evaluated the combination of PDS0101 (Versamune® HPV) and Keytruda in patients with HPV16-positive recurrent/metastatic head and neck squamous cell cancer.
📋 Key Facts
- Announced final topline survival data from Phase 2 VERSATILE-002 clinical trial on August 25, 2025.
- The trial evaluated PDS0101 (Versamune® HPV) in combination with Keytruda (pembrolizumab).
- Target population: Patients with HPV16-positive first-line recurrent and/or metastatic head and neck squamous cell cancer.
PDS Biotechnology Corp issued an 8-K to furnish a press release containing clinical program updates and financial results for the quarter ended June 30, 2025.
📋 Key Facts
- Report date: August 13, 2025
- Reporting period: Quarter ended June 30, 2025
- Content includes clinical program updates and financial results
- Information is 'furnished' under General Instruction B.2, not 'filed'
PDS Biotechnology Corporation announced the successful completion of patient recruitment for Stage 1 of its PDS01ADC clinical trial in combination with floxuridine (FUDR). The study met pre-set RECIST v1.1 criteria, allowing for expansion into Stage 2.
📋 Key Facts
- Completed patient recruitment in Stage 1 of the PDS01ADC + FUDR clinical trial (NCT05286814).
- The study was led by the National Cancer Institute (NCI), a component of the NIH.
- Met pre-set RECIST v1.1 criteria for expansion into Stage 2 of the study.
- Target indication: patients with metastatic colorectal cancer.
PDS Biotechnology Corp updated its corporate presentation deck on June 25, 2025. This filing serves as a formal notification of the update to the company's investor relations materials.
📋 Key Facts
- The company updated its corporate presentation deck on June 25, 2025.
- The updated presentation is filed as Exhibit 99.1.
- The filing was signed by Frank Bedu-Addo, Ph.D., President and CEO.
PDS Biotechnology Corp held its 2025 annual meeting of stockholders on June 11, 2025. The results included the election of two Class A directors and the approval of an amendment to the company's 2014 Equity Incentive Plan.
🚩 Red Flags
- Significant increase in authorized share pool (+48%) which may lead to future dilution for existing shareholders.
📋 Key Facts
- Annual Meeting held on June 11, 2025.
- Stockholders approved an amendment to the Third Amended and Restated PDS Biotechnology Corporation 2014 Equity Incentive Plan.
- The Amendment authorizes an additional 3,144,049 shares for issuance under the plan.
- Total shares issuable under the Restated Plan increased from 6,565,535 to 9,709,584 shares.
- Stephen Glover and Gregory Freitag were elected as Class A directors until the 2028 Annual Meeting.
- KPMG US LLP was ratified as the independent registered public accounting firm for fiscal year 2025.
- Quorum was established with 30,130,951 shares (65.97% of total voting shares) represented.
PDS Biotechnology Corporation announced the publication of three Versamune® HPV (PDS0101) abstracts at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. The presentation focuses on studies within the Head and Neck Cancer Poster Session.
📋 Key Facts
- Three abstracts regarding Versamune® HPV (PDS0101) were published on the ASCO website.
- The data was presented during the Head and Neck Cancer Poster Session held May 30 - June 3, 2025.
- The announcement is linked to the company's clinical development progress for its HPV-related therapeutic.
PDS Biotechnology Corporation announced the publication of three abstracts regarding its Versamune® HPV (PDS0101) studies. These abstracts are scheduled to be presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting.
📋 Key Facts
- Three Versamune® HPV abstracts were published on the ASCO website.
- The data pertains to PDS0101 studies.
- Presentations will occur during the Head and Neck Cancer Poster Session from May 30 to June 3, 2025, in Chicago, IL.
PDS Biotechnology Corporation issued an 8-K to furnish a press release containing clinical program updates and financial results for the quarter ended March 31, 2025.
📋 Key Facts
- Report date: May 14, 2025
- Reporting period: Quarter ended March 31, 2025
- Content includes clinical program updates and financial results via Exhibit 99.1
- The information is 'furnished' rather than 'filed', limiting liability under Section 18 of the Exchange Act.
PDS Biotechnology Corporation issued an 8-K to announce the release of preclinical immune response data for its investigational Infectimune® flu vaccine. The findings were presented at the IMMUNOLOGY2025™ Annual Meeting.
📋 Key Facts
- Announced updates on preclinical immune response data for the novel, investigational Infectimune® based flu vaccine.
- Data was featured at the American Association of Immunologists’ (AAI) IMMUNOLOGY2025™ Annual Meeting held May 3-7, 2025.
- The filing serves to incorporate a press release regarding these scientific updates into the company's official SEC records.
PDS Biotechnology Corporation entered into a $20 million securities purchase agreement involving the issuance of $22.22 million in Senior Secured Convertible Debentures and warrants for 1,000,000 shares. The proceeds are primarily being used to retire an existing Horizon Loan ($19M) and provide general working capital.
🚩 Red Flags
- Significant dilution potential via convertible debentures and warrants.
- Restrictive covenants: Company is prohibited from incurring new debt, granting liens, or selling/licensing assets in the ordinary course without permission.
- Cash maintenance covenant requiring a minimum cash balance of $15M (or principal + $3M), which could trigger default if liquidity dries up.
- Redemption right for holders to pull $500k/month starting August 2025, creating potential ongoing liquidity pressure.
- Variable Rate Transaction restriction: Limits the company's ability to raise future capital through certain types of convertible securities.
📋 Key Facts
- Total purchase price: $20,000,000
- Issuance of Senior Secured Convertible Debentures with aggregate principal amount of $22,222,222 (issued at an original issue discount).
- Warrants to purchase 1,000,000 shares of common stock at an exercise price of $2.52 per share.
- Debentures maturity date: April 20, 2028.
- Interest rate: Prime rate + 5% (minimum floor of 6%).
- $19 million of proceeds used to retire the Horizon Technology Finance Corporation loan.
- The company must maintain a cash balance equal to the lesser of $15.0 million or [outstanding principal + $3.0 million].
- Holders have the right to require redemption of up to $500,000 per month starting August 28, 2025.
PDS Biotechnology Corporation announced that Sir Richard Sykes will retire from the Board of Directors upon the expiration of his current term at the 2025 Annual Meeting of Stockholders.
📋 Key Facts
- Sir Richard Sykes notified the Company of his intention to retire and not stand for re-election.
- The departure is scheduled to coincide with the expiration of his term at the 2025 Annual Meeting of Stockholders.
- Notification date: April 22, 2025.
PDS Biotechnology Corporation issued an 8-K to furnish a press release containing clinical program updates and financial results for the fiscal year ended December 31, 2024.
📋 Key Facts
- Report date: March 27, 2025
- Reporting period: Fiscal year ended December 31, 2024
- Content includes clinical program updates and full-year financial results
- Information is 'furnished' under General Instruction B.2, not 'filed'
PDS Biotechnology Corp announced that the FDA has cleared its Investigational New Drug (IND) application for a combination therapy involving Versamune® MUC1 and PDS01ADC. This allows the company to proceed with clinical evaluation for treating metastatic colorectal carcinoma.
📋 Key Facts
- FDA clearance received on March 13, 2025, for an IND filed in January 2025.
- The study evaluates a combination of Versamune® MUC1 (formerly PDS0103) and PDS01ADC.
- Target indication: MUC1-positive unresectable, metastatic colorectal carcinoma in patients who failed previous treatment.
PDS Biotechnology Corporation announced the initiation of its VERSATILE-003 Phase 3 clinical trial, which is now open for patient enrollment. This represents a significant milestone in the company's clinical development pipeline.
📋 Key Facts
- Initiation of the VERSATILE-003 Phase 3 clinical trial announced on March 7, 2025.
- The trial is officially open for patient enrollment as of the filing date.
- The announcement was made via a press release incorporated by reference as Exhibit 99.1.
PDS Biotechnology Corp. entered into a securities purchase agreement to issue common stock, pre-funded warrants, and common warrants to raise approximately $11 million in gross proceeds. The funds are intended for R&D and general corporate purposes.
🚩 Red Flags
- Significant dilution: The issuance of over 7 million warrants (common and pre-funded) represents substantial potential future dilution for existing shareholders.
- Warrant overhang: Total shares issuable via warrants (~8.2M) exceeds the number of common shares being sold in this round (6.3M).
📋 Key Facts
- Gross proceeds expected: ~$11 million; Net proceeds expected: ~$10.05 million.
- Securities issued include 6,396,787 shares of common stock, up to 933,334 pre-funded warrants, and up to 7,330,121 common warrants.
- Offering price per share/common warrant: $1.50; Pre-funded warrant purchase price: $1.4999.
- Two directors participated in the offering at a slightly higher price of $1.66 per share and associated common warrant.
- Placement Agent (A.G.P./Alliance Global Partners) to receive a 7.0% cash fee on gross proceeds plus up to $75,000 in expense reimbursement.
- The company is subject to a 60-day lock-up for directors/officers and a 60-day restriction on further common stock issuances following closing.
PDS Biotechnology Corp announced the publication of clinical results in JAMA Oncology regarding its triple combination therapy (Versamune® HPV, PDS01ADC, and a PD-L1 ICI) for recurrent/metastatic HPV-associated cancers. The filing serves to incorporate a press release detailing these clinical responses into the company's official SEC records.
📋 Key Facts
- Clinical results published in JAMA Oncology on February 26, 2025.
- Study focuses on triple combination therapy: Versamune® HPV (PDS0101), PDS01ADC (IL-12 fused ADC), and a PD-L1 immune checkpoint inhibitor.
- Target population includes patients with recurrent/metastatic anal, cervical, head and neck, penile, vaginal, and vulvar cancers.
PDS Biotechnology Corporation announced the publication of clinical research results regarding its lead immunotherapy candidate, Versamune® HPV, in a peer-reviewed journal.
📋 Key Facts
- Publication date: February 24, 2025
- Subject matter: circulating tumor DNA (ctDNA) results for Versamune® HPV
- Journal: Clinical Cancer Research (American Association for Cancer Research)
- Lead candidate: Versamune® HPV
PDS Biotechnology Corporation reaffirmed its guidance to initiate the VERSATILE-003 Phase 3 clinical trial for Versamune® HPV plus pembrolizumab in Q1 2025. The company also updated its corporate presentation deck.
📋 Key Facts
- Reaffirmed intent to initiate VERSATILE-003 Phase 3 clinical trial in Q1 2025.
- The trial focuses on Versamune® HPV plus pembrolizumab for first-line treatment of recurrent and/or metastatic (R/M) HPV16-positive head and neck squamous cell cancer (HNSCC).
- Updated corporate presentation deck released on February 5, 2025.
PDS Biotechnology Corporation issued an 8-K to furnish its quarterly business update and financial results for the period ended September 30, 2024. The filing also includes an updated corporate presentation deck.
📋 Key Facts
- Report date: November 14, 2024
- Reporting period: Quarter ended September 30, 2024
- The company released a business update and financial results via press release (Exhibit 99.1)
- The company updated its corporate presentation deck (Exhibit 99.2)
PDS Biotechnology Corp announced the presentation of updated Phase 2 clinical trial data for Versamune® HPV at the ASTRO Annual Meeting 2024. The abstract received a Basic/Translational Science Award.
📋 Key Facts
- Updated IMMUNOCERV Phase 2 clinical trial data presented at ASTRO Annual Meeting 2024.
- Trial evaluates Versamune® HPV (formerly PDS0101) in combination with chemoradiation for locally advanced cervical cancer.
- Oral presentation delivered by Adam Grippin, M.D., Ph.D., of The University of Texas MD Anderson Cancer Center.
- The abstract was granted a Basic/Translational Science Award by the ASTRO Annual Meeting Steering Committee.
PDS Biotechnology Corporation filed an 8-K to announce the update of its corporate presentation deck as of September 16, 2024.
📋 Key Facts
- The company updated its corporate presentation deck on September 16, 2024.
- The updated presentation is filed as Exhibit 99.1.
PDS Biotechnology Corporation issued a press release regarding updated clinical trial data for its Versamune® HPV product presented at the ESMO Congress 2024. The data evaluates the combination of Versamune with KEYTRUDA for treating head and neck squamous cell carcinoma.
📋 Key Facts
- Updated data from the VERSATILE-002 trial was presented as a poster (879P) at the ESMO Congress 2024 on September 14, 2024.
- The study evaluates Versamune® HPV in combination with KEYTRUDA (pembrolizumab).
- Target indication is first-line (1L) treatment for patients with HPV16-positive recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).
PDS Biotechnology Corp has entered into an Amended and Restated At-Market Issuance Sales Agreement to facilitate the sale of up to $50.0 million in common stock. This agreement replaces a previous 2022 arrangement and allows for flexible, discretionary equity issuance through B. Riley Securities and H.C. Wainwright & Co.
🚩 Red Flags
- Potential for significant shareholder dilution through the issuance of up to $50 million in new common stock.
- The use of an ATM program often indicates a need for immediate liquidity, which can be a sign of cash runway constraints in micro-cap biotech firms.
📋 Key Facts
- Entered into an Amended and Restated At Market Issuance Sales Agreement on August 13, 2024.
- Aggregate offering price of up to $50.0 million in common stock.
- Agents: B. Riley Securities, Inc. and H.C. Wainwright & Co., LLC.
- Commission rate is 3% of gross sales proceeds.
- Sales will be conducted via an 'at-the-market' (ATM) offering under a previously effective Form S-3 registration statement.
PDS Biotechnology Corporation issued an 8-K to furnish its quarterly business update and financial results for the period ending June 30, 2024. The filing serves as a formal mechanism to release the press release containing these operational updates.
📋 Key Facts
- Report date: August 13, 2024
- Reporting period: Quarter ended June 30, 2024
- The company issued a business update and financial results via press release (Exhibit 99.1)
- Information is 'furnished' rather than 'filed', limiting liability under Section 18 of the Exchange Act.
PDS Biotechnology Corporation announced that updated data from its IMMUNOCERV Phase 2 clinical trial for Versamune® HPV will be presented at the 2024 ASTRO Annual Meeting. The presentation is scheduled to take place between September 29 and October 2, 2024.
📋 Key Facts
- Clinical Trial: IMMUNOCERV Phase 2 evaluating Versamune® HPV (formerly PDS0101).
- Indication: Treatment of locally advanced cervical cancer in combination with chemoradiation.
- Event: 2024 ASTRO Annual Meeting in Washington, DC and virtually.
- Presentation Date: September 29 through October 2, 2024.
PDS Biotechnology Corporation announced it will release its second quarter 2024 financial results and a business update on August 13, 2024.
📋 Key Facts
- Financial results for Q2 2024 to be reported on August 13, 2024.
- A business update will be provided simultaneously with the financial results.
- Results and updates will be released before the market opens on Tuesday, August 13, 2024.
PDS Biotechnology Corporation announced that an abstract featuring updated data from its VERSATILE-002 clinical trial has been accepted for presentation at the ESMO Congress 2024. The study evaluates Versamune® HPV in combination with KEYTRUDA® for patients with HPV16-positive recurrent/metastatic head and neck squamous cell carcinoma.
📋 Key Facts
- Trial Name: VERSATILE-002
- Treatment Combination: Versamune® HPV (formerly PDS0101) + KEYTRUDA® (pembrolizumab)
- Patient Population: HPV16-positive recurrent/metastatic head and neck squamous cell carcinoma (HNSCC)
- Event: ESMO Congress 2024 in Barcelona, Spain
- Presentation Date: September 13-17, 2024
PDS Biotechnology Corporation issued a press release regarding meeting minutes from the FDA concerning the Phase 3 clinical trial of its Versamune® immunotherapy for HPV16-positive head and neck squamous cell carcinoma. The company also updated its corporate presentation deck.
📋 Key Facts
- Received official minutes from an FDA meeting regarding next steps for a planned Phase 3 clinical trial.
- The investigational product is Versamune®, an immunotherapy targeting HPV16-positive head and neck squamous cell carcinoma.
- Updated corporate presentation deck was released on August 1, 2024.
PDS Biotechnology Corp held its 2024 annual meeting of stockholders on June 24, 2024. The primary outcome was the successful approval of an amendment to increase authorized common stock from 75 million to 150 million shares.
🚩 Red Flags
- Significant increase in authorized share count (doubled from 75M to 150M), which provides the company with capacity for future equity dilution via secondary offerings.
📋 Key Facts
- Annual Meeting held on June 24, 2024.
- Stockholders approved an amendment to the Eighth Amended and Restated Certificate of Incorporation.
- Authorized common stock increased from 75,000,000 to 150,000,000 shares.
- Frank Bedu-Addo, Ph.D. and Otis Brawley, M.D. were elected as Class C directors until the 2027 Annual Meeting.
- KPMG US LLP was ratified as the independent registered public accounting firm for fiscal year ending Dec 31, 2024.
- Quorum was established with 56.65% of shares (20,781,507) represented at the meeting.
PDS Biotechnology Corporation issued an 8-K to announce clinical data updates from its ongoing VERSATILE-002 Phase 2 trial and released an updated corporate presentation.
📋 Key Facts
- Announced update to data from the ongoing VERSATILE-002 Phase 2 clinical trial on June 12, 2024.
- Released an updated corporate presentation deck as of June 2024.
PDS Biotechnology Corporation issued an 8-K to furnish a press release containing its business update and financial results for the quarter ended March 31, 2024.
🚩 Red Flags
- No specific red flags identified in the text provided; standard quarterly earnings/update filing.
📋 Key Facts
- Report date: May 15, 2024
- Reporting period: Quarter ended March 31, 2024
- The filing is intended to furnish (not file) results of operations and financial condition under Item 2.02.
- Includes a business update via Exhibit 99.1.
PDS Biotechnology Corporation issued an 8-K to announce a Key Opinion Leader (KOL) event held on May 8, 2024. The event focused on discussing updated data from the VERSATILE-002 study and unmet clinical needs in HPV-positive head and neck squamous cell cancer (HNSCC).
📋 Key Facts
- Event Date: May 8, 2024.
- Topic: Discussion of positive, updated VERSATILE-002 data.
- Clinical Focus: Unmet needs in HPV-positive head and neck squamous cell cancer (HNSCC).
- Format: Key Opinion Leader (KOL) event.
PDS Biotechnology Corporation filed an 8-K to announce the update of its corporate presentation deck as of May 8, 2024.
📋 Key Facts
- The company updated its corporate presentation deck on May 8, 2024.
- The updated presentation is included in the filing as Exhibit 99.1.
PDS Biotechnology Corporation has appointed Stephan F. Toutain as its new Chief Operations Officer (COO), effective May 1, 2024. The appointment includes a base salary of $450,000 and an equity inducement grant of 200,000 stock options.
📋 Key Facts
- Stephan F. Toutain appointed as Chief Operations Officer (COO) effective May 1, 2024.
- Annual base salary set at $450,000 with a potential 40% performance bonus.
- Inducement grant of 200,000 shares of common stock via the 2019 Inducement Plan.
- Options vest over four years: 25% on the first anniversary and 75% in equal monthly installments thereafter.
- Toutain brings extensive experience from companies including Anavex Life Sciences, Alnylam Pharmaceuticals, Celgene, and Johnson & Johnson.
PDS Biotechnology Corporation issued an 8-K to announce its clinical development strategy update and financial results for the fiscal year ended December 31, 2023. The company also updated its corporate presentation deck.
📋 Key Facts
- Announced updates to clinical development strategy as of March 27, 2024.
- Released financial results for the fiscal year ended December 31, 2023.
- Updated the company's corporate presentation deck (Exhibit 99.2).
PDS Biotechnology Corporation announced the publication of preclinical research results and the issuance of a new patent by the USPTO regarding its Infectimune® infectious disease vaccine platform.
📋 Key Facts
- The company issued a press release on March 13, 2024.
- A new patent was issued by the United States Patent and Trademark Office (USPTO).
- Preclinical research findings related to the Infectimune® platform were published.
PDS Biotechnology Corp announced the retirement of its Chief Medical Officer, Dr. Lauren V. Wood, effective January 22, 2024, and the simultaneous appointment of Dr. Kirk V. Shepard as her successor. Additionally, the company amended its 2019 Inducement Plan to increase the pool of reserved common stock by 1 million shares.
🚩 Red Flags
- Expansion of share pool in Inducement Plan (potential future dilution).
📋 Key Facts
- Dr. Lauren V. Wood retired as Chief Medical Officer effective January 22, 2024.
- The retirement was not due to any disagreement regarding Company operations, policies, or practices.
- Dr. Kirk V. Shepard appointed as the new Chief Medical Officer, effective January 22, 2024.
- Amended the 2019 Inducement Plan to increase reserved shares from 1,100,000 to 2,100,000.